19 recruiting. 19 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 19 | Recruiting 19 |
Follow Neurodevelopmental Disorders: new trials by email Literature Review of Neurodevelopmental Disorders trials Research Report on Neurodevelopmental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Semaglutide in Youth With Autism Spectrum Disorder Glucagon-like peptide-1 receptor agonist：Semaglutide, Lifestyle Management (LSM) Counseling - Autism Spectrum Disorder, Obesity | Phase 4 | Recruiting | Children's Hospital Medical Center, Cincinnati | 42 | 2026-10-18 | 2026-11-09 |
| Evaluation of Foquest in Adults 65 Years and Older With ADHD Methylphenidate hydrochloride extended-release capsules - Attention Deficit Hyperactivity Disorder | Phase 4 | Recruiting | Dar Clinical Research Inc. | 36 | 2026-10-06 | 2026-10-07 |
| Buspirone for Anxiety in Autistic Youth buspirone, Placebo - Anxiety, Autism Spectrum Disorder | Phase 4 | Recruiting | Massachusetts General Hospital | 20 | 2026-09-01 | 2026-09-17 |
| Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities Deutetrabenazine Oral Capsule - Tardive Dyskinesia, Intellectual Disability | Phase 4 | Recruiting | University Hospitals Cleveland Medical Center | 25 | 2026-06-22 | 2026-07-06 |
| Medication Treatment of ADHD in Pediatric Epilepsy methylphenidate hydrochloride (Jornay PM) - ADHD - Attention Deficit Disorder With Hyperactivity | Phase 4 | Recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 25 | 2026-05-29 | 2026-07-29 |
| Atomoxetine and Executive Function in PTSD Atomoxetine, Placebo - Posttraumatic Stress Disorder With Attention Defic | Phase 4 | Recruiting | VA Office of Research and Development | 160 | 2026-04-01 | 2026-07-07 |
| Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants CNS Stimulant, Placebo, CNS Stimulant open label first phase - ADHD - Attention Deficit Disorder With Hyperactivity, Irritability | Phase 4 | Recruiting | Milton S. Hershey Medical Center | 136 | 2026-03-05 | 2026-04-20 |
| Treating Young Children With Attention Deficit Hyperactivity Disorder Guanfacine (GUA), Methylphenidate (MPH) - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 4 | Recruiting | Children's Hospital Medical Center, Cincinnati | 370 | 2026-02-16 | 2026-09-14 |
| The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine Adderall XR (mixed salts amphetamine), Placebo - Attention Deficit Hyperactivity Disorder (ADHD), Autism | Phase 4 | Recruiting | Gagan Joshi | 196 | 2026-02-01 | 2026-03-06 |
| R61/33 - VR Study Phase 4 Meta Quest 3 VR Headset with noise cancelling headphones - Attention Deficit Hyperactivity Disorder | Phase 4 | Recruiting | Rutgers, The State University of New Jersey | 252 | 2025-09-09 | 2026-01-28 |
| An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening Methylphenidate Hydrochloride Extended Release Capsule - Attention-deficit/Hyperactivity Disorder | Phase 4 | Recruiting | NYU Langone Health | 30 | 2025-01-29 | 2026-04-29 |
| A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD). Dyanavel XR, Placebo - Fatigue, Attention Deficit Hyperactivity Disorder | Phase 4 | Recruiting | Rochester Center for Behavioral Medicine | 50 | 2024-09-01 | 2024-11-21 |
| Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD 100mg SPN-812, Placebo - Attention-Deficit/Hyperactivity Disorder | Phase 4 | Recruiting | Supernus Pharmaceuticals, Inc. | 286 | 2024-03-19 | 2026-10-05 |
| Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints Methylphenidate, Placebo - Posttraumatic Stress Disorder (PTSD) | Phase 4 | Recruiting | VA Office of Research and Development | 70 | 2024-02-05 | 2026-08-19 |
| AWARE: Management of ADHD in Autism Spectrum Disorder Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant. - ADHD, Autism Spectrum Disorder | Phase 4 | Recruiting | Daniel Coury | 500 | 2023-10-01 | 2026-10-22 |
| Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability Metformin, Placebo, Lifestyle Intervention - Intellectual Disability, Developmental Disability | Phase 4 | Recruiting | Centre for Addiction and Mental Health | 100 | 2023-02-28 | 2026-03-31 |
| Use of Hyperpolarized 129Xe MR Lung Imaging in Infants 129Xe - Lungs; Developmental Disorder | Phase 4 | Recruiting | Children's Hospital Medical Center, Cincinnati | 12 | 2020-05-06 | 2026-01-07 |
| Stimulant Effects on Disruptive Behavior Stimulant - Attention Deficit Hyperactivity Disorder, Problem Behavior | Phase 4 | Recruiting | Matthew J O'Brien, PhD, BCBA-D | 10 | 2018-10-01 | 2025-03-17 |
| Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder Immediate-release Methylphenidate - Attention Deficit Disorder With Hyperactivity | Phase 4 | Recruiting | Hospital de Clinicas de Porto Alegre | 600 | 2002-02-01 | 2016-11-01 |
Attention Deficit Disorder with Hyperactivity (14) · Autism Spectrum Disorder (4) · Autistic Disorder (3) · Developmental Disabilities (3) · Intellectual Disability (2) · Obesity (2) · Stress Disorders, Post-Traumatic (2) · Aggression (1) · Anxiety Disorders (1) · Brain Injuries, Traumatic (1) · Caregiver Burden (1) · Epilepsy (1) · Fatigue (1) · Movement Disorders (1) · Problem Behavior (1)
Mental Disorders (19) · Attention Deficit and Disruptive Behavior Disorders (14) · Child Development Disorders, Pervasive (4) · Nervous System Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Behavior (3) · Behavioral Symptoms (3) · Central Nervous System Diseases (3) · Body Weight (2) · Brain Diseases (2) · Neurobehavioral Manifestations (2) · Neurologic Manifestations (2) · Nutrition Disorders (2)
Methylphenidate (7) · Central Nervous System Stimulants (2) · 5,10-dihydro-5-methylphenazine (1) · Adderall (1) · Adenosine Monophosphate (1) · Amphetamine (1) · Atomoxetine Hydrochloride (1) · Buspirone (1) · Clinical Trials, Phase II as Topic (1) · Counseling (1) · Dexmethylphenidate Hydrochloride (1) · Guanfacine (1) · Lisdexamfetamine Dimesylate (1) · Metformin (1) · SLI381 (1)
Children's Hospital Medical Center, Cincinnati (3) · VA Office of Research and Development (2) · Centre for Addiction and Mental Health (1) · Daniel Coury (1) · Dar Clinical Research Inc. (1) · Gagan Joshi (1) · Hospital de Clinicas de Porto Alegre (1) · Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (1) · Massachusetts General Hospital (1) · Matthew J O'Brien, PhD, BCBA-D (1) · Milton S. Hershey Medical Center (1) · NYU Langone Health (1) · Rochester Center for Behavioral Medicine (1) · Rutgers, The State University of New Jersey (1) · Supernus Pharmaceuticals, Inc. (1)
United States (16) · Canada (3) · Brazil (1)
Daniel Coury, MD (1) · Gagan Joshi, MD (1) · Jason Woods, PhD (1) · Jay Salpekar, MD (1) · Joel Young, MD (1) · Joseph Hull, PhD (1) · Joshua M Langberg, PhD (1) · Judy van Stralen, MD, FRCPC (1) · Karen Kuhlthau, PhD (1) · Lenard Adler, MD (1) · Matthew J O'Brien, PhD (1) · Melinda Mahabee-Gittens, MD, PhD (1) · Rebecca C. Hendrickson, MD PhD (1) · Stephen Ruedrich, MD (1)
I01RX004823 (1), R61MH131632 (1)